Drugs / ALN-AGT01 RVR
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06675565 | Nov 2024 → Sep 2025 | — | Alnylam Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07553442 | Apr 2026 → Apr 2028 expected | hypertensive disorder | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-AGT01 RVR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06675565 ↗ |
| Route | Subcutaneous | “ALN-AGT01 RVR will be administered subcutaneously (SC)” NCT06675565 ↗ |